Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges

Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in t...

Full description

Saved in:
Bibliographic Details
Published inCurrent HIV/AIDS reports Vol. 17; no. 1; pp. 26 - 34
Main Authors Cao, Wei, Hsieh, Evelyn, Li, Taisheng
Format Journal Article
LanguageEnglish
Published New York Springer US 01.02.2020
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years. Recent Findings Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Summary Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.
AbstractList The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.PURPOSE OF REVIEWThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.RECENT FINDINGSContinuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.
The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years. Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.
Purpose of ReviewThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.Recent FindingsContinuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART.SummaryGreat progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.
Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years. Recent Findings Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Summary Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.
Author Hsieh, Evelyn
Cao, Wei
Li, Taisheng
Author_xml – sequence: 1
  givenname: Wei
  surname: Cao
  fullname: Cao, Wei
  organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
– sequence: 2
  givenname: Evelyn
  surname: Hsieh
  fullname: Hsieh, Evelyn
  organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Section of Rheumatology, Department of Internal Medicine, Allergy and Immunology, Yale School of Medicine
– sequence: 3
  givenname: Taisheng
  surname: Li
  fullname: Li, Taisheng
  email: litsh@263.net
  organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31939111$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1OGzEUha2KqkDoC3RRWeqmmyn22Jmxu6gUhVIiISGV0K3leO4kpjN2sD38PT1OA7RlwcpX9neOzvXZRzvOO0DoAyVfKCH1YaRUEl4QKgtCeC2K2zdoj465KNi4rnae50rsov0YLwlhXPLqHdplVDJJKd1Dv8_Wyfb23rolngfQqQeXcOsDnjRDlyK-sWmFT2a_Diezo3NsHZ6urNNf8flgDMQIEftrCHh-4_ERGN3kC-0a_BN6bd3GdbrSXQduCfEAvW11F-H94zlCF8ff59OT4vTsx2w6OS0Mr3kqFlzoqqTaUCDcmEVtNBmTRgKVeeB1y-tGEA6iAWo0ZKwq27YVJSMVBSHYCH3b-q6HRQ-NyRsF3al1sL0Od8prq_5_cXallv5aVVJITuts8PnRIPirAWJSvY0Guk478ENUJWNCSrn5xRH69AK99ENweb1McVFWjMkyUx__TfQc5amHDIgtYIKPMUCrjE06Wb8JaDtFidpUrraVq1y5-lO5us3S8oX0yf1VEduKYoZzN-Fv7FdUD-t-v1k
CitedBy_id crossref_primary_10_1007_s12144_025_07419_5
crossref_primary_10_1186_s12879_024_09065_x
crossref_primary_10_1097_QAI_0000000000003053
crossref_primary_10_1186_s12879_021_06644_0
crossref_primary_10_1371_journal_pone_0238564
crossref_primary_10_1002_jmv_29824
crossref_primary_10_1007_s11657_021_00890_0
crossref_primary_10_3389_fpubh_2022_1056915
crossref_primary_10_1111_jcmm_17534
crossref_primary_10_3389_fpubh_2024_1485516
crossref_primary_10_2147_DDDT_S369832
crossref_primary_10_3389_fphar_2023_1268597
crossref_primary_10_1186_s12879_025_10703_1
crossref_primary_10_1186_s12981_024_00682_9
crossref_primary_10_1017_S2045796023000240
crossref_primary_10_1097_CM9_0000000000002918
crossref_primary_10_3390_v16111713
crossref_primary_10_1097_CM9_0000000000001824
crossref_primary_10_2174_1570162X19666210910144433
crossref_primary_10_3390_ijerph19105910
crossref_primary_10_1093_infdis_jiae302
crossref_primary_10_1186_s12879_022_07113_y
crossref_primary_10_3389_fpubh_2022_800839
crossref_primary_10_1186_s12889_024_20728_x
crossref_primary_10_3389_fmicb_2020_604993
crossref_primary_10_2147_DDDT_S406255
crossref_primary_10_3389_fphar_2020_00800
crossref_primary_10_1097_QAI_0000000000003047
crossref_primary_10_1007_s40121_023_00877_z
crossref_primary_10_1007_s10508_021_02155_w
crossref_primary_10_1016_j_ijnss_2023_06_003
crossref_primary_10_1002_cpdd_1309
crossref_primary_10_1099_jmm_0_001949
crossref_primary_10_1097_CM9_0000000000003317
crossref_primary_10_1097_CM9_0000000000003202
crossref_primary_10_3390_ijms21030748
crossref_primary_10_1002_ijc_35242
crossref_primary_10_1186_s12879_024_09624_2
crossref_primary_10_1089_apc_2022_0192
crossref_primary_10_1186_s12944_024_02224_8
crossref_primary_10_1186_s12981_024_00680_x
crossref_primary_10_12677_tcm_2024_1311441
crossref_primary_10_1093_jac_dkad370
crossref_primary_10_2196_42469
crossref_primary_10_1097_NJH_0000000000000824
crossref_primary_10_1093_ve_veab094
crossref_primary_10_1038_s41598_024_80749_9
crossref_primary_10_1097_CM9_0000000000002500
crossref_primary_10_1186_s12879_023_08359_w
crossref_primary_10_1080_07853890_2024_2427910
crossref_primary_10_3389_fpubh_2022_902537
crossref_primary_10_3390_ijerph191610220
crossref_primary_10_1111_hiv_13252
crossref_primary_10_1186_s12953_024_00230_3
crossref_primary_10_1186_s12903_023_03752_y
crossref_primary_10_1089_aid_2020_0273
crossref_primary_10_1016_j_jgar_2022_01_017
crossref_primary_10_1016_S2352_3018_21_00316_7
crossref_primary_10_1136_sextrans_2021_055019
crossref_primary_10_3389_fonc_2023_1248790
crossref_primary_10_3390_vaccines11050921
crossref_primary_10_2147_IJWH_S374976
crossref_primary_10_1016_j_jot_2021_04_002
crossref_primary_10_3389_fimmu_2023_1153790
crossref_primary_10_2174_1570162X21666230524141239
crossref_primary_10_1016_j_watres_2021_117803
crossref_primary_10_1371_journal_pone_0284405
crossref_primary_10_3389_fpubh_2022_1054765
crossref_primary_10_4103_jehp_jehp_126_23
crossref_primary_10_1186_s12888_022_04366_4
crossref_primary_10_12677_ACM_2023_1371557
crossref_primary_10_1111_hiv_13758
crossref_primary_10_3389_fcimb_2023_1249837
crossref_primary_10_1080_21505594_2024_2373105
crossref_primary_10_3389_fmed_2022_965836
crossref_primary_10_1016_j_jgar_2023_01_002
crossref_primary_10_1007_s10461_024_04420_0
crossref_primary_10_1093_ofid_ofab309
crossref_primary_10_1371_journal_pgph_0000956
crossref_primary_10_1038_s41467_023_41051_w
crossref_primary_10_3390_ph17010115
crossref_primary_10_1016_j_jinf_2021_12_034
crossref_primary_10_1007_s00198_020_05584_w
crossref_primary_10_1016_S2666_7568_22_00003_4
crossref_primary_10_5812_archcid_145233
crossref_primary_10_1177_09564624241283983
crossref_primary_10_1097_MD_0000000000023638
crossref_primary_10_1097_CM9_0000000000002939
crossref_primary_10_1186_s12985_023_02193_x
crossref_primary_10_1089_apc_2024_0045
crossref_primary_10_1097_CM9_0000000000001447
crossref_primary_10_1097_CM9_0000000000002898
crossref_primary_10_1016_j_scitotenv_2023_162589
crossref_primary_10_1097_CM9_0000000000003358
crossref_primary_10_1186_s12981_024_00678_5
crossref_primary_10_1007_s15010_020_01508_2
crossref_primary_10_1093_cid_ciaa835
crossref_primary_10_1016_j_jiac_2021_02_003
Cites_doi 10.1001/jamainternmed.2013.3728
10.7326/0003-4819-151-4-200908180-00005
10.1086/649215
10.1111/imr.12065
10.1097/COH.0000000000000230
10.1186/s12879-016-1928-x
10.1056/NEJMoa1506816
10.1038/nrneph.2015.9
10.7448/IAS.19.1.20659
10.1016/S1473-3099(14)70946-6
10.1093/cid/cir552
10.1038/s41598-018-29202-2
10.1371/journal.pone.0165110
10.1111/hiv.12171
10.1097/QAI.0b013e3182845cc7
10.1111/hiv.12421
10.1097/QAI.0b013e3181ba1c31
10.1186/1471-2210-4-2
10.1371/journal.pone.0047289
10.1186/s12879-018-3158-x
10.1007/s00705-018-3839-1
10.1111/nep.12031
10.1097/QAD.0b013e32801022eb
10.1179/1528433614Z.0000000005
10.1038/sj.cr.7290362
10.1097/01.aids.0000304710.10036.2b
10.1097/QAD.0000000000000125
10.1371/journal.pone.0182335
10.1016/S0140-6736(13)62187-X
10.1002/art.10411
10.1093/cid/ciu086
10.1097/QAD.0b013e328355ced2
10.3760/cma.j.issn.0366-6999.20132557
10.1097/QAI.0000000000000927
10.1371/journal.pone.0003918
10.1016/S1473-3099(15)70060-5
10.1111/hiv.12607
10.1136/annrheumdis-2013-204807
ContentType Journal Article
Copyright The Author(s) 2020
This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
K9.
7X8
5PM
DOI 10.1007/s11904-019-00478-x
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
ProQuest Health & Medical Complete (Alumni)

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1548-3576
EndPage 34
ExternalDocumentID PMC6989417
31939111
10_1007_s11904_019_00478_x
Genre Journal Article
Review
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: NCATS NIH HHS
  grantid: UL1 TR001863
GroupedDBID ---
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
29F
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40D
40E
5GY
5VS
6J9
6NX
875
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSNA
ACZOJ
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEGXH
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
B-.
BA0
BDATZ
BGNMA
C1A
C6C
CAG
COF
CS3
CSCUP
CUW
DDRTE
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HG6
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
IWAJR
IXC
IXD
IXE
I~Z
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
MA-
NPVJJ
NQJWS
NU0
O9-
O9J
P9S
PF0
PT4
QOR
QOS
R89
R9I
ROL
RPX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z7U
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
NPM
ABRTQ
K9.
7X8
5PM
ID FETCH-LOGICAL-c474t-b48a621ac1e04ccb7ca050d9e19a0547f47d804e8de1caec1e62fff823061e883
IEDL.DBID U2A
ISSN 1548-3568
1548-3576
IngestDate Thu Aug 21 18:20:45 EDT 2025
Fri Jul 11 08:28:39 EDT 2025
Fri Jul 25 09:58:09 EDT 2025
Wed Feb 19 02:30:56 EST 2025
Tue Jul 01 01:53:31 EDT 2025
Thu Apr 24 23:00:54 EDT 2025
Fri Feb 21 02:29:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Continuum of care
Highly active antiretroviral therapy
National Free Antiretroviral Treatment Program
Human immunodeficiency virus
Acquired immune deficiency syndrome
Multidisciplinary care
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-b48a621ac1e04ccb7ca050d9e19a0547f47d804e8de1caec1e62fff823061e883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://link.springer.com/10.1007/s11904-019-00478-x
PMID 31939111
PQID 2348263392
PQPubID 2044209
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6989417
proquest_miscellaneous_2338999319
proquest_journals_2348263392
pubmed_primary_31939111
crossref_citationtrail_10_1007_s11904_019_00478_x
crossref_primary_10_1007_s11904_019_00478_x
springer_journals_10_1007_s11904_019_00478_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-02-01
PublicationDateYYYYMMDD 2020-02-01
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Current HIV/AIDS reports
PublicationTitleAbbrev Curr HIV/AIDS Rep
PublicationTitleAlternate Curr HIV/AIDS Rep
PublicationYear 2020
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Lv, Zhang, Shi, Zheng, Li, Chen, Wu, Jiang, Li, Gong (CR46) 2015; 74
Zhang, Pan, Yu, Wen, Zhao (CR3) 2005; 15
Zhang, Liu, Sun, Sun, Lu (CR37) 2017; 12
(CR26) 2017; 10
Klatt, Chomont, Douek, Deeks (CR41) 2013; 254
Guo, Cheng, Hsieh, Du, Fu, Peng, Li, Song, Routy, Li (CR11) 2018; 19
Carey, Puls, Amin, Losso, Phanupak, Foulkes, Mohapi, Crabtree-Ramirez, Jessen, Kumar (CR10) 2015; 15
Wu, Norris, Liu, Li, Su, Zhu, Wang (CR40) 2014; 27
(CR14) 2015; 8
Xu, Peng, Peng, Ji, Chen, Wang, Lu, Xie, Sun, Wang, Wu (CR38) 2018; 163
(CR9) 2014; 383
Zhang, Haberer, Wang, Zhao, Ma, Zhao, Yu, Goosby (CR4) 2007; 21
(CR7) 2011; 29
Li, Chang, Han, Zhuang, Li, Liu, Liu, Bao, Zhang, Song (CR35) 2016; 16
Massanella, Fromentin, Chomont (CR43) 2016; 11
Li, Han, Xie, Gu, Li, Wang, Lv, Song, Li, Routy, Ishida, Iwamoto, Li (CR17) 2014; 28
CR2
Zhang, Zhu, Wu, Dou, Zhang, Kleinman, Bulterys, Wu, Ma, Zhao, Liu, Fang, Liu, Cai, Shang (CR28) 2014; 14
Li, Guo, Li, Zhang, Han, Lye, He, Lu, Xie, Huang (CR8) 2014; 127
Rosenberg, Naicker, Winkler, Kopp (CR21) 2015; 11
(CR12) 2018; 57
Zhao, Feng, Hu, Li, Zuo, Yan, Zhang, Cao, Xu, Li, Li, Liao, Ruan, Shao, Xing (CR36) 2018; 8
Routy, Angel, Patel, Kanagaratham, Radzioch, Kema, Gilmore, Ancuta, Singer, Jenabian (CR44) 2015; 16
Goldbach-Mansky, Wilson, Fleischmann, Olsen, Silverfield, Kempf, Kivitz, Sherrer, Pucino, Csako (CR47) 2009; 151
He, Xing, Ruan, Hong, Cheng, Hu, Xin, Wei, Feng, Hsi (CR16) 2012; 7
Freiberg, Chang, Kuller, Skanderson, Lowy, Kraemer, Butt, Bidwell Goetz, Leaf, Oursler, Rimland, Rodriguez Barradas, Brown, Gibert, McGinnis, Crothers, Sico, Crane, Warner, Gottlieb, Gottdiener, Tracy, Budoff, Watson, Armah, Doebler, Bryant, Justice (CR19) 2013; 173
Teeraananchai, Kerr, Amin, Ruxrungtham, Law (CR18) 2017; 18
Tang, Mao, Tang, Han, Xu, Li (CR32) 2018; 18
CR13
Brown, Qaqish (CR23) 2006; 20
Kusunoki, Yamazaki, Kitasato, Beppu, Aoki, Kawai (CR49) 2004; 4
Ye, Zeng, Li, Zhang, Fang, Luo, Qiu, Han, Li (CR24) 2010; 53
Cao, Gong, Han, Xie, Li, Zhang, Li, Song, Zhu, Li (CR22) 2013; 18
Wang, Li, Zhang, Han, Zhang, Zhu, Li (CR30) 2012; 26
Li, Wu, Dai, Qiu, Han, Xie, Zhu, Li (CR42) 2011; 53
Zhang, Wang, Zhou, Han, Xie, Qiu, Guo, Li, Wang, Ghanem (CR6) 2013; 15
Lundgren, Babiker, Gordin, Emery, Grund, Sharma, Avihingsanon, Cooper, Fatkenheuer, Llibre (CR15) 2015; 373
Cao, Song, Li, Qiu, Xie, Han, Lyu, Wang, Fan (CR34) 2014; 53
Ma, Zhao, Yu, Bulterys, Robinson, Zhao, Dou, Chiliade, Wei, Zhang (CR39) 2010; 50
Luo, Zeng, Li, Lv, Wang, Guo, Han, Xie, Qiu, Li, Song, Zhu, Zhang, Li, Ye, He, Lu, Huang, Tang, Wang, Zhang, Gao, Lei, Wu, Sun, Bai, Li (CR20) 2014; 58
Xie, Han, Qiu, Li, Li, Song, Wang, Thio, Li (CR29) 2016; 19
Li, Xie, Li, Routy, Li, Han, Qiu, Lv, Song, Sun, Zhang, Wang, Jiang (CR48) 2015; 16
Li, Dai, Kuang, Jiang, Han, Qiu, Xie, Zuo, Li (CR5) 2008; 3
Li, Zhang, Lu, Cai, Wu, Sun, Zhao, Zhang, Cao (CR25) 2017; 165
Hong, Zhou (CR1) 1986; 25
Li, Xie, Han, Wang, Zhu, Wang, Lv, Guo, Qiu, Li (CR31) 2016; 72
Xie, Hsieh, Sun, Wang, Lv, Fan, Li (CR33) 2017; 12
Tao, Younger, Fan, Wang, Lipsky (CR45) 2002; 46
(CR27) 2019; 37
ENCORE1 Study Group: Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (478_CR9) 2014; 383
H Li (478_CR25) 2017; 165
FD Zhang (478_CR37) 2017; 12
F Guo (478_CR11) 2018; 19
Y Li (478_CR31) 2016; 72
Y Cao (478_CR22) 2013; 18
T Li (478_CR5) 2008; 3
D Carey (478_CR10) 2015; 15
MS Freiberg (478_CR19) 2013; 173
C Zhang (478_CR6) 2013; 15
AZ Rosenberg (478_CR21) 2015; 11
H Tang (478_CR32) 2018; 18
FJ Zhang (478_CR3) 2005; 15
TT Brown (478_CR23) 2006; 20
S Teeraananchai (478_CR18) 2017; 18
478_CR2
478_CR13
R Goldbach-Mansky (478_CR47) 2009; 151
J Xie (478_CR29) 2016; 19
F Zhang (478_CR4) 2007; 21
X Tao (478_CR45) 2002; 46
AIDS Professional Group (478_CR26) 2017; 10
N Kusunoki (478_CR49) 2004; 4
T Li (478_CR8) 2014; 127
H Wang (478_CR30) 2012; 26
Y Li (478_CR17) 2014; 28
T Li (478_CR48) 2015; 16
Y Hong (478_CR1) 1986; 25
W Cao (478_CR34) 2014; 53
S Zhao (478_CR36) 2018; 8
M Massanella (478_CR43) 2016; 11
X He (478_CR16) 2012; 7
Y Xu (478_CR38) 2018; 163
Y Ma (478_CR39) 2010; 50
Society of Tropical Diseases and Parasitology of Chinese Medical Association (478_CR27) 2019; 37
QW Lv (478_CR46) 2015; 74
AIDS Professional Group (478_CR14) 2015; 8
J Xie (478_CR33) 2017; 12
AIDS Professional Group (478_CR7) 2011; 29
J Wu (478_CR40) 2014; 27
J Lundgren (478_CR15) 2015; 373
F Zhang (478_CR28) 2014; 14
Y Ye (478_CR24) 2010; 53
HP Li (478_CR35) 2016; 16
AIDS and Hepatitis C Professional Group (478_CR12) 2018; 57
L Luo (478_CR20) 2014; 58
NR Klatt (478_CR41) 2013; 254
T Li (478_CR42) 2011; 53
JP Routy (478_CR44) 2015; 16
References_xml – volume: 14
  start-page: 1065
  issue: 11
  year: 2014
  end-page: 1072
  ident: CR28
  article-title: HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study
  publication-title: Lancet Infect Dis
– volume: 53
  start-page: 276
  issue: 2
  year: 2010
  end-page: 278
  ident: CR24
  article-title: HIV infection: an independent risk factor of peripheral arterial disease
  publication-title: J Acquir Immune Defic Syndr
– volume: 58
  start-page: 1459
  issue: 10
  year: 2014
  end-page: 1466
  ident: CR20
  article-title: Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV
  publication-title: Clin Infect Dis
– volume: 26
  start-page: 1755
  issue: 14
  year: 2012
  end-page: 1763
  ident: CR30
  article-title: Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort
  publication-title: Aids
– volume: 18
  start-page: 272
  issue: 1
  year: 2018
  ident: CR32
  article-title: "Late for testing, early for antiretroviral therapy, less likely to die": results from a large HIV cohort study in China, 2006-2014
  publication-title: BMC Infect Dis
– volume: 28
  start-page: 521
  issue: 4
  year: 2014
  end-page: 530
  ident: CR17
  article-title: CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission
  publication-title: Aids
– volume: 151
  start-page: 229
  issue: 4
  year: 2009
  end-page: 240
  ident: CR47
  article-title: Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial
  publication-title: Ann Intern Med
– volume: 163
  start-page: 2233
  issue: 8
  year: 2018
  end-page: 2237
  ident: CR38
  article-title: Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014-2017
  publication-title: Arch Virol
– volume: 18
  start-page: 256
  issue: 4
  year: 2017
  end-page: 266
  ident: CR18
  article-title: Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis
  publication-title: HIV Med
– volume: 16
  start-page: 49
  issue: 2
  year: 2015
  end-page: 56
  ident: CR48
  article-title: Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety
  publication-title: HIV Clin Trials
– volume: 383
  start-page: 1474
  issue: 9927
  year: 2014
  end-page: 1482
  ident: CR9
  article-title: (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
  publication-title: Lancet
– volume: 15
  start-page: 540
  issue: 62
  year: 2013
  end-page: 545
  ident: CR6
  article-title: The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted
  publication-title: J Acquir Immune Defic Syndr
– volume: 11
  start-page: 234
  issue: 2
  year: 2016
  end-page: 241
  ident: CR43
  article-title: Residual inflammation and viral reservoirs: alliance against an HIV cure
  publication-title: Curr Opin HIV AIDS
– volume: 16
  start-page: 605
  issue: 1
  year: 2016
  ident: CR35
  article-title: The prevalence of drug resistance among treatment-naive HIV-1-infected individuals in China during pre- and post-2004
  publication-title: BMC Infect Dis
– volume: 254
  start-page: 326
  issue: 1
  year: 2013
  end-page: 342
  ident: CR41
  article-title: Immune activation and HIV persistence: implications for curative approaches to HIV infection
  publication-title: Immunol Rev
– volume: 8
  start-page: 12273
  issue: 1
  year: 2018
  ident: CR36
  article-title: Prevalence of transmitted HIV drug resistance in antiretroviral treatment naive newly diagnosed individuals in China
  publication-title: Sci Rep
– volume: 29
  start-page: 629
  issue: 10
  year: 2011
  end-page: 640
  ident: CR7
  article-title: Society of Infectious Diseases Chinese Medical Association: guidelines for diagnosis and treatment of HIV/AIDS in China (2011)
  publication-title: ZHONGHUA CHUAN RAN BING ZA ZHI
– volume: 27
  start-page: 838
  issue: 11
  year: 2014
  end-page: 871
  ident: CR40
  article-title: The prevalence of HIV drug resistance among treatment-failure individuals and treatment-naive individuals in China: a meta-analysis
  publication-title: Biomed Environ Sci
– volume: 37
  start-page: 129
  issue: 3
  year: 2019
  end-page: 138
  ident: CR27
  article-title: Expert consensus on diagnosis and treatment of HIV infection combined with nontuberculosis mycobacterium infection
  publication-title: Chin J Infect Dis
– volume: 21
  start-page: S143
  issue: Suppl 8(1473–5571 (Electronic))
  year: 2007
  end-page: S148
  ident: CR4
  article-title: The Chinese free antiretroviral treatment program: challenges and responses
  publication-title: Aids
– volume: 19
  start-page: 20659
  issue: 1
  year: 2016
  ident: CR29
  article-title: Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study
  publication-title: J Int AIDS Soc
– volume: 20
  start-page: 2165
  issue: 17
  year: 2006
  end-page: 2174
  ident: CR23
  article-title: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review
  publication-title: Aids
– volume: 8
  start-page: 385
  issue: 5
  year: 2015
  end-page: 401
  ident: CR14
  article-title: Society of Infectious Diseases, Chinese Medical Association: third edition of the guidelines for diagnosis and treatment of HIV/AIDS (2015)
  publication-title: Chin J Clin Infect Dis
– volume: 173
  start-page: 614
  issue: 8
  year: 2013
  end-page: 622
  ident: CR19
  article-title: HIV infection and the risk of acute myocardial infarction
  publication-title: JAMA Intern Med
– ident: CR2
– volume: 18
  start-page: 307
  issue: 4
  year: 2013
  end-page: 312
  ident: CR22
  article-title: Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naive patients in mainland China: a multicenter cross-sectional study
  publication-title: Nephrology(Carlton)
– volume: 4
  start-page: 2
  issue: 1471–2210 (Electronic)
  year: 2004
  ident: CR49
  article-title: Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts
  publication-title: BMC Pharmacol
– volume: 10
  start-page: 81
  issue: 2
  year: 2017
  end-page: 90
  ident: CR26
  article-title: Society of Infectious Diseases Chinese Medical Association, Society of Tropical Diseases and Parasitology of Chinese Medical Association: expert consensus on diagnosis and treatment of HIV infection combined with mycobacterium tuberculosis infection
  publication-title: Chin J Clin Infect Dis
– volume: 12
  start-page: e0165110
  issue: 2
  year: 2017
  ident: CR37
  article-title: An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China
  publication-title: PLoS One
– volume: 74
  start-page: 1078
  issue: 6
  year: 2015
  end-page: 1086
  ident: CR46
  article-title: Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial
  publication-title: Ann Rheum Dis
– volume: 25
  start-page: 436
  issue: 7
  year: 1986
  end-page: 439
  ident: CR1
  article-title: Clinical pathological conference: fever, cough and progressive dyspnea
  publication-title: Chin J Internal Med
– volume: 50
  start-page: 264
  issue: 2
  year: 2010
  end-page: 271
  ident: CR39
  article-title: Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China
  publication-title: Clin Infect Dis
– volume: 57
  start-page: 867
  issue: 12
  year: 2018
  end-page: 884
  ident: CR12
  article-title: Society of Infectious Diseases Chinese Medical Association, Chinese Center for Disease Control and Prevention: [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)]
  publication-title: Zhonghua Nei Ke Za Zhi
– volume: 53
  start-page: 944
  issue: 9
  year: 2011
  end-page: 951
  ident: CR42
  article-title: Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy
  publication-title: Clin Infect Dis
– volume: 127
  start-page: 59
  issue: 1
  year: 2014
  end-page: 65
  ident: CR8
  article-title: An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China
  publication-title: Chin Med J
– volume: 46
  start-page: 1735
  issue: 7
  year: 2002
  end-page: 1743
  ident: CR45
  article-title: Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study
  publication-title: Arthritis Rheum
– volume: 7
  start-page: e47289
  issue: 10
  year: 2012
  ident: CR16
  article-title: A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey
  publication-title: PLoS One
– volume: 12
  start-page: e0182335
  issue: 8
  year: 2017
  ident: CR33
  article-title: Delays in HIV diagnosis and associated factors among patients presenting with advanced disease at a tertiary care hospital in Beijing, China
  publication-title: PLoS One
– volume: 16
  start-page: 48
  issue: 1
  year: 2015
  end-page: 56
  ident: CR44
  article-title: Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy
  publication-title: HIV Med
– volume: 11
  start-page: 150
  issue: 3
  year: 2015
  end-page: 160
  ident: CR21
  article-title: HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment
  publication-title: Nat Rev Nephrol
– ident: CR13
– volume: 165
  start-page: 578
  issue: 6
  year: 2017
  end-page: 581
  ident: CR25
  article-title: Expert consensus on management of HIV infection combined with chronic renal diseases
  publication-title: Chin J AIDS&STD
– volume: 53
  start-page: 537
  issue: 7
  year: 2014
  end-page: 541
  ident: CR34
  article-title: Zhou B et al: [Clinical characteristics of 297 newly diagnosed Chinese HIV/AIDS patients]
  publication-title: Zhonghua Nei Ke Za Zhi
– volume: 3
  start-page: e3918
  issue: 12
  year: 2008
  ident: CR5
  article-title: Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort
  publication-title: PLoS One
– volume: 72
  start-page: 39
  issue: 1
  year: 2016
  end-page: 45
  ident: CR31
  article-title: Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL
  publication-title: J Acquir Immune Defic Syndr
– volume: 19
  start-page: 440
  year: 2018
  end-page: 450
  ident: CR11
  article-title: Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study
  publication-title: HIV Med
– volume: 373
  start-page: 795
  issue: 9
  year: 2015
  end-page: 807
  ident: CR15
  article-title: Initiation of antiretroviral therapy in early asymptomatic HIV infection
  publication-title: N Engl J Med
– volume: 15
  start-page: 877
  issue: 11–12
  year: 2005
  end-page: 882
  ident: CR3
  article-title: Current progress of China’s free ART program
  publication-title: Cell Res
– volume: 15
  start-page: 793
  issue: 7
  year: 2015
  end-page: 802
  ident: CR10
  article-title: Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study
  publication-title: Lancet Infect Dis
– volume: 173
  start-page: 614
  issue: 8
  year: 2013
  ident: 478_CR19
  publication-title: JAMA Intern Med
  doi: 10.1001/jamainternmed.2013.3728
– volume: 10
  start-page: 81
  issue: 2
  year: 2017
  ident: 478_CR26
  publication-title: Chin J Clin Infect Dis
– volume: 53
  start-page: 537
  issue: 7
  year: 2014
  ident: 478_CR34
  publication-title: Zhonghua Nei Ke Za Zhi
– volume: 37
  start-page: 129
  issue: 3
  year: 2019
  ident: 478_CR27
  publication-title: Chin J Infect Dis
– volume: 151
  start-page: 229
  issue: 4
  year: 2009
  ident: 478_CR47
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-151-4-200908180-00005
– volume: 50
  start-page: 264
  issue: 2
  year: 2010
  ident: 478_CR39
  publication-title: Clin Infect Dis
  doi: 10.1086/649215
– volume: 254
  start-page: 326
  issue: 1
  year: 2013
  ident: 478_CR41
  publication-title: Immunol Rev
  doi: 10.1111/imr.12065
– volume: 11
  start-page: 234
  issue: 2
  year: 2016
  ident: 478_CR43
  publication-title: Curr Opin HIV AIDS
  doi: 10.1097/COH.0000000000000230
– ident: 478_CR13
– volume: 165
  start-page: 578
  issue: 6
  year: 2017
  ident: 478_CR25
  publication-title: Chin J AIDS&STD
– volume: 16
  start-page: 605
  issue: 1
  year: 2016
  ident: 478_CR35
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-016-1928-x
– volume: 373
  start-page: 795
  issue: 9
  year: 2015
  ident: 478_CR15
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1506816
– volume: 57
  start-page: 867
  issue: 12
  year: 2018
  ident: 478_CR12
  publication-title: Zhonghua Nei Ke Za Zhi
– volume: 11
  start-page: 150
  issue: 3
  year: 2015
  ident: 478_CR21
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2015.9
– volume: 19
  start-page: 20659
  issue: 1
  year: 2016
  ident: 478_CR29
  publication-title: J Int AIDS Soc
  doi: 10.7448/IAS.19.1.20659
– volume: 14
  start-page: 1065
  issue: 11
  year: 2014
  ident: 478_CR28
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(14)70946-6
– volume: 53
  start-page: 944
  issue: 9
  year: 2011
  ident: 478_CR42
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir552
– volume: 8
  start-page: 12273
  issue: 1
  year: 2018
  ident: 478_CR36
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-29202-2
– volume: 12
  start-page: e0165110
  issue: 2
  year: 2017
  ident: 478_CR37
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0165110
– volume: 16
  start-page: 48
  issue: 1
  year: 2015
  ident: 478_CR44
  publication-title: HIV Med
  doi: 10.1111/hiv.12171
– volume: 15
  start-page: 540
  issue: 62
  year: 2013
  ident: 478_CR6
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0b013e3182845cc7
– volume: 18
  start-page: 256
  issue: 4
  year: 2017
  ident: 478_CR18
  publication-title: HIV Med
  doi: 10.1111/hiv.12421
– volume: 53
  start-page: 276
  issue: 2
  year: 2010
  ident: 478_CR24
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0b013e3181ba1c31
– volume: 4
  start-page: 2
  issue: 1471–2210 (Elec
  year: 2004
  ident: 478_CR49
  publication-title: BMC Pharmacol
  doi: 10.1186/1471-2210-4-2
– volume: 7
  start-page: e47289
  issue: 10
  year: 2012
  ident: 478_CR16
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0047289
– volume: 18
  start-page: 272
  issue: 1
  year: 2018
  ident: 478_CR32
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-018-3158-x
– volume: 163
  start-page: 2233
  issue: 8
  year: 2018
  ident: 478_CR38
  publication-title: Arch Virol
  doi: 10.1007/s00705-018-3839-1
– volume: 18
  start-page: 307
  issue: 4
  year: 2013
  ident: 478_CR22
  publication-title: Nephrology(Carlton)
  doi: 10.1111/nep.12031
– volume: 20
  start-page: 2165
  issue: 17
  year: 2006
  ident: 478_CR23
  publication-title: Aids
  doi: 10.1097/QAD.0b013e32801022eb
– volume: 16
  start-page: 49
  issue: 2
  year: 2015
  ident: 478_CR48
  publication-title: HIV Clin Trials
  doi: 10.1179/1528433614Z.0000000005
– volume: 25
  start-page: 436
  issue: 7
  year: 1986
  ident: 478_CR1
  publication-title: Chin J Internal Med
– volume: 15
  start-page: 877
  issue: 11–12
  year: 2005
  ident: 478_CR3
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7290362
– volume: 8
  start-page: 385
  issue: 5
  year: 2015
  ident: 478_CR14
  publication-title: Chin J Clin Infect Dis
– volume: 21
  start-page: S143
  issue: Suppl 8(1473–55
  year: 2007
  ident: 478_CR4
  publication-title: Aids
  doi: 10.1097/01.aids.0000304710.10036.2b
– volume: 28
  start-page: 521
  issue: 4
  year: 2014
  ident: 478_CR17
  publication-title: Aids
  doi: 10.1097/QAD.0000000000000125
– volume: 12
  start-page: e0182335
  issue: 8
  year: 2017
  ident: 478_CR33
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0182335
– volume: 383
  start-page: 1474
  issue: 9927
  year: 2014
  ident: 478_CR9
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62187-X
– volume: 46
  start-page: 1735
  issue: 7
  year: 2002
  ident: 478_CR45
  publication-title: Arthritis Rheum
  doi: 10.1002/art.10411
– volume: 58
  start-page: 1459
  issue: 10
  year: 2014
  ident: 478_CR20
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu086
– volume: 26
  start-page: 1755
  issue: 14
  year: 2012
  ident: 478_CR30
  publication-title: Aids
  doi: 10.1097/QAD.0b013e328355ced2
– volume: 127
  start-page: 59
  issue: 1
  year: 2014
  ident: 478_CR8
  publication-title: Chin Med J
  doi: 10.3760/cma.j.issn.0366-6999.20132557
– volume: 72
  start-page: 39
  issue: 1
  year: 2016
  ident: 478_CR31
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000000927
– volume: 3
  start-page: e3918
  issue: 12
  year: 2008
  ident: 478_CR5
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0003918
– volume: 15
  start-page: 793
  issue: 7
  year: 2015
  ident: 478_CR10
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(15)70060-5
– volume: 27
  start-page: 838
  issue: 11
  year: 2014
  ident: 478_CR40
  publication-title: Biomed Environ Sci
– volume: 29
  start-page: 629
  issue: 10
  year: 2011
  ident: 478_CR7
  publication-title: ZHONGHUA CHUAN RAN BING ZA ZHI
– ident: 478_CR2
– volume: 19
  start-page: 440
  year: 2018
  ident: 478_CR11
  publication-title: HIV Med
  doi: 10.1111/hiv.12607
– volume: 74
  start-page: 1078
  issue: 6
  year: 2015
  ident: 478_CR46
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204807
SSID ssj0034946
Score 2.527402
SecondaryResourceType review_article
Snippet Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and...
The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led...
Purpose of ReviewThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 26
SubjectTerms Acquired immune deficiency syndrome
AIDS
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
Drug therapy
HIV
Human immunodeficiency virus
Medicine
Medicine & Public Health
Section Editor
The Global Epidemic (SH Vermund
The Global Epidemic (SH Vermund, Section Editor)
Topical Collection on The Global Epidemic
Toxicity
Title Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges
URI https://link.springer.com/article/10.1007/s11904-019-00478-x
https://www.ncbi.nlm.nih.gov/pubmed/31939111
https://www.proquest.com/docview/2348263392
https://www.proquest.com/docview/2338999319
https://pubmed.ncbi.nlm.nih.gov/PMC6989417
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS9xAEB-sQimIVPsw1h5b6Ld2aR67yabfwqk9W2yh3hX7KextNvRQc2LuUPrXd2aT3HG1Cv0WksnmMbszs_P4DcBb1PEGtyUJF0YqLkQa8lTbgktlTegXVF1MDv2Tr_FgJD6fybO2KKzust27kKST1MtiN9RdlDGRcoI4VBwtxw1Je3ecxaMw6-Qv4a24miK0xXkkY9WWyvx7jFV1dMfGvJsq-Ve81Kmho6ew1dqPLGsYvg1rttqBxydthHwHNhs_HGvKi57B-TeUCZeT3zgYG3ZJ5QwtVZYR8kbNyBHLBsc_PmTHB6dsUjHXUfsjO527Voq2ZpTkyYY3U3ZgKZm-Zroq2Hd72fSWQPq2HUv9HEZHh8P-gLcNFrgRiZjxsVA6DgNtAusLY8aJ0b70i9QGKR6IpBRJoXxhVWEDoy2SxWFZlhSbiwOrVPQC1qtpZXeBqag0Miz02CRS4J5GRwQKGaGxoKX1lfAg6P5zblr0cWqCcZEvcZOJNznyJne8yW89eLe456rB3niQer9jX96uwzoPCbsnjtAI9ODN4jKuIAqL6MpO50RDGIMpyiIPXjbcXjwOT0akDjxIVubBgoDQuVevVJNfDqWbOnOKIPHgfTdjlq91_1fs_R_5K3gSkgPApZHvw_rsem5fo5U0G_dgI_v088thDx71437PLZE_TsgKRw
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS-QwEB_EAxXkON9VTyP4TYN9pG1635ZV2VVXQVfxW8mmKS5qV-wud_jX30wfK-sL_FbaafqYJPNLZuY3ALto4zUuS0IutC-5EJHLI2US7kujXTuh7GLa0O-cB61rcXLr31Y0OZQL88Z_f5A7aLEoTiLiRGwoOeLFHwJXyhS-1wya9axLLCtFJhEicO75gawSZD5uY9IIvUOW7wMk33hJC-Nz_At-VqiRNUo1L8CUyRZhplP5xRdhvtx9Y2VS0RLcX-BM8Nh_wcZYtw4lZ4hPWYP4NnJG26-s1b45aLQPr1g_Y0Ud7T_salQUUDQ5o9BO1v07YIeGQuhzprKEXZrHsqIEyldFWPJluD4-6jZbvCqrwLUIxZD3hFSB6yjtGFto3Qu1sn07iYwT4YEIUxEm0hZGJsbRyqBY4KZpSh65wDFSeiswnQ0yswZMeqn23UT1dOgLXMkoj6ggPYQIyje2FBY49X-OdcU5TqUvHuJXtmTSTYy6iQvdxP8s2Bvf81QybnwpvVmrL65GXx67xNgTeAj9LNgZX8ZxQ84QlZnBiGSIWTDCGciC1VLb48fhSY-MgAXhRD8YCxAn9-SVrH9XcHNTPU7hhBbs1z3m9bU-_4r174lvw2yr2zmLz9rnpxsw59IWQBFIvgnTw-eR-Y04adjbKgbIfzhfBqg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED9NIKFJEwI2tvA1T9rbZjUfTuLsrWqpWjbYNMrEW-Q6jlYBKSKtQPvruXOSlo6BtLcouTgfZ_t-9t39DuAj2niNy5KYCx1KLkTi80SZjIfSaN_NKLuYNvSPT6L-mTg6D88fZPHbaPfGJVnlNBBLUzFtXWd5a5H4hnaMoicSTnSHkiOKXMWVinXUdqJOMxcT94rNL0JczoMwknXazL_bWDZNj_Dm47DJv3yn1iT1NmC9xpKsXSl_E16YYgvWjmtv-Ra8qvbkWJVq9BouvuP8cDX-g42xYRNgzhC1sjaxcJSMNmVZf_Cr1R50T9m4YLa69hd2OrNlFU3JKOCTDW8nrGsosL5kqsjYT3NV1ZlA-bo0S_kGznqHw06f18UWuBaxmPKRkCryPaU94wqtR7FWbuhmifESPBBxLuJMusLIzHhaGRSL_DzPyU8XeUbKYBtWiklh3gGTQa5DP1MjHYcC1zcqIILIAIGDCo0rhQNe859TXTORU0GMy3TBoUy6SVE3qdVNeufAp_k91xUPx7PSe4360npMlqlPPD5RgIDQgQ_zyziayEWiCjOZkQzxDSY4LznwttL2_HF4MiDT4EC81A_mAsTUvXylGP-2jN1UpVN4sQOfmx6zeK2nv2Ln_8Tfw9qPbi_9Njj5ugsvfdoXsNHle7AyvZmZfQRP09GBHR_3dA0O7w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimizing+Treatment+for+Adults+with+HIV%2FAIDS+in+China%3A+Successes+over+Two+Decades+and+Remaining+Challenges&rft.jtitle=Current+HIV%2FAIDS+reports&rft.au=Cao%2C+Wei&rft.au=Hsieh%2C+Evelyn&rft.au=Li%2C+Taisheng&rft.date=2020-02-01&rft.pub=Springer+US&rft.issn=1548-3568&rft.eissn=1548-3576&rft.volume=17&rft.issue=1&rft.spage=26&rft.epage=34&rft_id=info:doi/10.1007%2Fs11904-019-00478-x&rft_id=info%3Apmid%2F31939111&rft.externalDocID=PMC6989417
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1548-3568&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1548-3568&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1548-3568&client=summon